<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (AZA) in <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy related MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is not well established </plain></SENT>
<SENT sid="1" pm="."><plain>54 patients (42 t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 12 t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 71% of whom had complex karyotype, received AZA for at least one cycle (median 4 cycles) </plain></SENT>
<SENT sid="2" pm="."><plain>The overall response rate (ORR) was 39% in the whole cohort and 62% in patients who received â‰¥4 cycles </plain></SENT>
<SENT sid="3" pm="."><plain>One, 2 and 3 year OS was 36%, 14% and 8% respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Female gender (p=0.01) and ECOG 0-1 (p=0.04) were associated with significantly better OS, while karyotype and marrow blast percentage had no significant impact </plain></SENT>
<SENT sid="5" pm="."><plain>By comparison with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated in the same program, t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> had a similar response rate (38% vs 45% in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, p=0.53), but significantly shorter OS (2 year OS of 14% vs 33.9%, p=0.0005) </plain></SENT>
<SENT sid="6" pm="."><plain>However, in a multivariate analysis performed in <z:hpo ids='HP_0000001'>all</z:hpo> patients (de novo and therapy related cases), only complex karyotype and high IPSS, and not etiology (i.e. de novo versus therapy related), had a significant impact on OS </plain></SENT>
<SENT sid="7" pm="."><plain>Nine (15%) patients received allogeneic stem cell transplantation, 4 of whom were still alive </plain></SENT>
</text></document>